var data={"title":"Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6735?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207103\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pegetron;</li>\n      <li>Pegetron RediPen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207120\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihepaciviral, Nucleoside (Anti-HCV);</li>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207106\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Peginterferon and ribavirin combination therapy (<b>without</b> the addition of another HCV antiviral agent) is <b>not </b>recommended in HCV treatment guidelines (treatment-naive or treatment-experienced). Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a. Refer to individual monographs for dosing (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic hepatitis C:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegetron peginterferon alfa-2b component: SubQ: 1.5 mcg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>and</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegetron ribavirin component: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HCV genotype 1 (treatment-naive):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">66 to 80 kg: 1,000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">81 to 105 kg: 1,200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;105 kg: 1,400 mg/day (three 200 mg capsules in the morning and four 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HCV nongenotype 1 (treatment-naive):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">66 to 85 kg: 1,000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;85 kg: 1,200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Re-treatment (relapser or nonresponder): Any HCV genotype:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;65 kg: 800 mg/day (two 200 mg capsules in the morning and two 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">66 to 85 kg: 1,000 mg/day (two 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">86 to 105 kg: 1,200 mg/day (three 200 mg capsules in the morning and three 200 mg capsules in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;105 kg: 1,400 mg/day (three 200 mg capsules in the morning and four 200 mg capsules in the evening)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991839\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;50 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, use caution and monitor closely for signs/symptoms of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;50 mL/minute: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum creatinine &gt;2 mg/dL: Permanently discontinue therapy in any patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989125\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment (Child-Pugh class A or B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, limited data shows C<sub>max</sub> increases with increasing severity of hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indirect bilirubin &gt;5 mg/dL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HCV genotype 1 (treatment-naive): Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HCV nongenotype 1 (treatment-naive): Continue current peginterferon alfa-2b dose; decrease ribavirin dose to 600 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relapser or nonresponder (any HCV genotype): Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin &gt;2.5 times ULN or indirect bilirubin &gt;4 mg/dL (for &gt;4 weeks): Permanently discontinue both peginterferon alfa-2b and ribavirin in any patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AST/ALT 2 times baseline <b>and</b> &gt;10 times ULN: Permanently discontinue both peginterferon alfa-2b and ribavirin in any patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062248\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207121\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment): </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hemoglobin:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV genotype 1 (treatment-naive):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week; decrease ribavirin dose by 200 mg/day if receiving &le;1200 mg/day or by 400 mg/day if receiving 1400 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL <b>or</b> &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV nongenotype 1 (treatment-naive):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose to 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by one-half; decrease ribavirin dose to 600 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL <b>or</b> &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relapser or nonresponder (any HCV genotype):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;10 g/dL: Continue current peginterferon alfa-2b dose; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week; decrease ribavirin dose by 200 mg/day if receiving &le;1000 mg/day or by 400 mg/day if receiving &ge;1200 mg/day (first reduction), and by an additional 200 mg/day (second reduction) if necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemoglobin &lt;8.5 g/dL <b>or</b> &lt;12 g/dL after ribavirin dose is decreased for 4 weeks and stable cardiac disease: Permanently discontinue both peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>White blood cells:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype):  WBC &lt;1.5 x 10<sup>9</sup>/L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV nongenotype 1 (treatment-naive): WBC &lt;1.5 x 10<sup>9</sup>/L: Decrease peginterferon alfa2b-dose by one-half.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Any patient with WBC &lt;1.0 x 10<sup>9</sup>/L: Permanently discontinue peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Neutrophils:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype):  Neutrophils &lt;0.75 x 10<sup>9</sup>/L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV nongenotype 1 (treatment-naive): Neutrophils &lt;0.75 x 10<sup>9</sup>/L: Decrease peginterferon alfa-2b dose by one-half.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Any patient with neutrophils &lt;0.5 x 10<sup>9</sup>/L: Permanently discontinue peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Platelets:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV genotype 1 (treatment-naive) or relapser/nonresponder (any HCV genotype): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Platelet count &lt;50 x 10<sup>9</sup>/L: Decrease peginterferon alfa-2b dose in increments of 0.5 mcg/kg/week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Platelet count &lt;25 x 10<sup>9</sup>/L: Permanently discontinue peginterferon alfa-2b and ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCV nongenotype 1 (treatment-naive): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Platelet count &lt;80 x 10<sup>9</sup>/L: Decrease peginterferon alfa-2b dose by one-half.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Platelet count &lt;50 x 10<sup>9</sup>/L: Permanently discontinue peginterferon alfa-2b and ribavirin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012044\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Combination package:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pegetron:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Ribavirin 200 mg (56s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection, powder for reconstitution: Peginterferon alfa-2b: 50 mcg [contains polysorbate 80 and sucrose; two single-dose vials with diluent]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pegetron:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Ribavirin 200 mg (56s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection, powder for reconstitution: Peginterferon alfa-2b: 80 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pegetron:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Ribavirin 200 mg (56s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection, powder for reconstitution: Peginterferon alfa-2b: 100 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pegetron:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Ribavirin 200 mg (70s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection, powder for reconstitution: Peginterferon alfa-2b: 120 mcg [contains polysorbate 80 and sucrose; two single-dose Redipens]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pegetron:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule: Ribavirin 200 mg (84s, 98s)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection, powder for reconstitution: Peginterferon alfa-2b: 150 mcg [contains polysorbate 80 and sucrose; two single-dose vials with diluent or two single-dose Redipens]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234133\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207091\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49322200\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Ribavirin is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207090\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Combination therapy for the treatment of chronic hepatitis C in patients with compensated liver disease,  including treatment-naive patients and those who have failed prior treatment with pegylated or nonpegylated interferon alpha and ribavirin combination therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations: </i></b>Peginterferon and ribavirin combination therapy (<b>without</b> the addition of another HCV antiviral agent) is <b>not </b>recommended in HCV treatment guidelines (treatment-naive or treatment-experienced). Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a (AASLD/IDSA 2015). Recommended regimen depends on HCV genotype and whether patient is treatment-naive or treatment-experienced. Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116837\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\"> <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207080\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (32% to 65%), headache (39% to 62%), rigors (43% to 48%), insomnia (21% to 40%), chills (22% to 39%), irritability (17% to 35%), depression (12% to 34%), dizziness (10% to 21%), lack of concentration (5% to 19%), anxiety (8% to 16%), pain (4% to 13%), right upper quadrant pain (7% to 12%), emotional lability (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (17% to 45%), pruritus (13% to 29%), xeroderma (8% to 26%), skin rash (9% to 24%), diaphoresis (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (7% to 30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (24% to 43%), anorexia (9% to 35%), diarrhea (12% to 22%), decreased appetite (8% to 18%), vomiting (8% to 16%), abdominal pain (3% to 15%), xerostomia (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (16% to 34%), hemolytic anemia (&le;28%), neutropenia (2% to 26%; grade 4: &le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (10% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (5% to 59%), inflammation at injection site (20% to 27%), erythema at injection site (10% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (26% to 56%), arthralgia (16% to 34%), weakness (4% to 28%), musculoskeletal pain (&le;21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (10% to 27%), flu-like symptoms (2% to 27%), cough (14% to 19%), pharyngitis (11% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (32% to 46%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (&le;10%), chest pain (2% to 10%), hypertension (&le;5%), hypotension (&le;5%), palpitations (&le;5%), flushing (1% to 5%), syncope (1% to 5%), peripheral edema (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Nervousness (&le;10%), paresthesia (2% to 10%), agitation (1% to 10%), confusion (&le;5%), drowsiness (&le;5%), hyperesthesia (&le;5%), hypoesthesia (&le;5%), apathy (2% to 5%), hypertonia (2% to 5%), malaise (2% to 5%), vertigo (2% to 5%), aggressive behavior (1% to 5%), migraine (1% to 5%), tremor (1% to 5%), memory impairment (2% to 4%), lethargy (&le;3%), amnesia (2% to 3%), outbursts of anger (2%), disturbed sleep (&le;2%), crying (1% to 2%), restlessness (1% to 2%), intolerance to temperature (&le;1%), suicidal ideation (&le;1%), psychosis (&le;1%; including hallucinations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythematous maculopapular rash (&le;5%), erythema (2% to 5%), hair disease (abnormal hair texture: 2% to 5%), skin photosensitivity (2% to 5%), eczema (1% to 5%), rash at injection site (1% to 4%), hyperhidrosis (2% to 3%), injection site pruritus (1% to 3%), dermatitis (2%), night sweats (1% to 2%), cellulitis (&le;1%), cheilitis (&le;1%), psoriasis (&le;1%), desquamation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperthyroidism (&le;10%), hypothyroidism (&le;10%), hypermenorrhea (5% to 10%), menstrual disease (5% to 10%), amenorrhea (2% to 5%), increased thirst (2% to 5%), decreased libido (1% to 5%), hyperuricemia (1% to 2%), increased thyroid stimulating hormone level (1%), dehydration (&le;1%), increased amylase (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (4% to 10%), constipation (3% to 10%), dysgeusia (3% to 10%), gingival hemorrhage (&le;5%), flatulence (2% to 5%), glossitis (2% to 5%), loose stools (2% to 5%), stomatitis (1% to 5%; including aphthous and ulcerative), gastroesophageal reflux disease (1% to 2%), oral mucosa ulcer (1% to 2%), abdominal distention (1%), burning sensation of mouth (1%), gastritis (1%), stomach discomfort (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Prostatitis (2% to 5%), herpes labialis (1% to 2%), erectile dysfunction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (2% to 10%; grades 3/4: &le;7%), thrombocytopenia (&le;7%), lymphadenopathy (&le;5%), lymphocytopenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (2% to 5%), herpes simplex infection (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5% to 6%), muscle spasm (2% to 5%), limb pain (3% to 4%), ostealgia (1%), neck pain (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (2% to 10%), eye pain (&le;5%), conjunctivitis (2% to 5%), lacrimal dysfunction (2% to 5%), xerophthalmia (2% to 3%), photophobia (&le;1%), retinal exudates (&le;1%), visual disturbance (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Auditory impairment (2% to 5%), otitis media (2% to 5%), tinnitus (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Polyuria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (8% to 10%), nonproductive cough (5% to 10%), rhinorrhea (&le;5%), dyspnea on exertion (4% to 5%), respiratory tract disease (2% to 5%), bronchitis (1% to 5%), nasal congestion (1% to 5%), sinusitis (1% to 5%), pharyngolaryngeal pain (2% to 4%), epistaxis (2%), upper respiratory tract infection (&le;2%), post nasal drip (1%), dry nose (&le;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207094\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polyethylene glycol (PEG), interferons, ribavirin, or any component of the formulation; autoimmune hepatitis or history of autoimmune disease; decompensated liver disease; history of or pre-existing severe psychiatric disorder; uncontrolled thyroid dysfunction; epilepsy; severe renal dysfunction (CrCl &lt;50 mL/minute); males with a pregnant female partner; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207078\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Anemia and severe cytopenias have has been observed in patients receiving the interferon/ribavirin combination. Rarely, aplastic anemia has been observed with peginterferon alfa-2b therapy. Use peginterferon alfa-2b with caution in patients with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. Reduce dose with decreased neutrophil, platelet count, or hemoglobin and discontinue therapy if significant decreases in neutrophil (&lt;0.5 x 10<sup>9</sup>/L),  platelet counts (&lt;25 x 10<sup>9</sup>/L), or hemoglobin &lt;8.5 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebrovascular events (ischemic and hemorrhagic) have been observed in patients receiving peginterferon alfa-2b, including patients without risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: High-dose peginterferon alfa-2b has been associated with significant obtundation and coma, including cases of encephalopathy (usually elderly patients), and rarely seizures. May cause CNS depression (somnolence, fatigue), which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colitis: Serious cases of ischemic and ulcerative colitis have been observed within 12 weeks of initiation of peginterferon alfa-2b therapy; discontinue therapy in suspected/confirmed colitis; upon discontinuation of therapy, resolution of colitis is usually observed within 1-3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Maintain adequate hydration; hypotension associated with dehydration has been observed with use alfa interferons (including peginterferon alfa-2b); fluid replacement may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental/periodontal disorders: Have been reported with ribavirin and interferon therapy; patients should be instructed to brush teeth twice daily and have regular dental exams.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Interferon therapy is associated with immune-mediated reactions including erythema multiforme, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: Hemolytic anemia is a significant toxicity, usually occurring within 1 to 4 weeks, and may worsen underlying cardiac disease; use caution and assess cardiac disease before initiation; avoid use in patients with history of significant or unstable cardiac disease. Patients with renal dysfunction and/or those &gt;50 years of age should be carefully assessed for development of anemia. If any deterioration in cardiovascular status occurs, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Rare cases of acute hypersensitivity (eg, anaphylaxis, angioedema, bronchoconstriction) have been observed with alfa-interferon therapy. Discontinue therapy immediately with signs of hypersensitivity and treat appropriately. Transient skin reactions may not warrant treatment interruption in the absence of more severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: New onset or aggravation of existing hypertriglyceridemia (sometimes severe) has been observed with use of peginterferon alfa-2b; monitor lipids with therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Ophthalmologic disorders (including retinal hemorrhages, cotton wool spots, and retinal artery or vein obstruction) have occurred rarely in patients using peginterferon alfa-2b. Ophthalmic examinations are recommended prior to therapy for all patients and periodically during therapy for patients at risk for retinopathy (eg, diabetes mellitus or hypertension). Patients presenting with ocular symptoms (eg, loss of visual acuity or vision field) at any time during therapy should receive a prompt ophthalmic examination. Consider discontinuation of therapy with new or worsening ophthalmologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Otic effects: Hearing impairment and/or loss have been observed with use of peginterferon alfa-2b.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has been reported with use; interrupt therapy for signs/symptoms of pancreatitis. Discontinue therapy in suspected/confirmed pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b>[Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening autoimmune disorders.</b> Patients predisposed to developing autoimmune disorders may be at greater risk (use is contraindicated in patients with history of autoimmune disease). Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use peginterferon alfa-2b with caution in patients with ischemic or thromboembolic cardiac disease, heart failure, hypertension or arrhythmias; avoid use in patients with severe cardiac disease within previous 6 months; discontinuation of therapy may be indicated with worsening cardiovascular status. Rarely, cardiomyopathy has been reported in patients without prior history of cardiac disease; cardiomyopathy may be reversible following discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endocrine disorders: Use peginterferon alfa-2b with caution in patients with endocrine disorders; hyper/hypothyroid have been observed (infrequently) with use of peginterferon alfa-2b; changes may or may not reverse with therapy discontinuation; obtain thyroid stimulating hormone (TSH) levels if symptomatic; avoid initiating therapy or discontinue existing therapy with uncontrolled TSH levels; diabetes mellitus and hyperglycemia have been observed with use; monitor glucose; dosage adjustments of antidiabetic therapy may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epilepsy: Use is contraindicated in patients with epilepsy.  Rarely, high-dose peginterferon alfa-2b has been associated with seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: Use of ribavirin may be associated with increased uric acid levels (due to hemolysis); monitor for signs/symptoms of gout (particularly in predisposed patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemoglobinopathies: Avoid use in patients with hemoglobinopathies (eg, sickle-cell anemia, thalassemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use in decompensated hepatic disease is contraindicated; use with caution in patients with mild-to-moderate hepatic impairment; discontinue treatment with worsening hepatic function or signs/symptoms of hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b>[Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening infectious disorders.</b> Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases. Investigate the etiology of any persistent fever during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders: <b>[Canadian Boxed Warning]: Alpha interferons cause or aggravate fatal or life-threatening ischemic disorders.</b> Monitor patients closely. Discontinue therapy for persistently severe or worsening symptoms. Symptom resolution generally occurs upon discontinuation of therapy in most cases, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[Canadian Boxed Warning]: Life-threatening or fatal psychiatric adverse events (psychosis, aggressive behavior, severe depression, suicidal behavior/ideation and suicide) have been reported in patients with and without previous psychiatric symptoms. Additional CNS adverse effects (confusion, mental status changes) have also been reported. Use with extreme caution in patients with a history of pre-existing psychiatric disorders who report a history of severe depression.</b> Use in patients with preexisting or a history of <b>severe</b> psychiatric disorders is contraindicated. Onset of psychiatric or CNS adverse effects (including clinical depression) warrants careful neuropsychiatric monitoring during and for 6 months following discontinuation of therapy. Discontinue use with worsening or persistent symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psoriasis: Exacerbation of disease has been observed with use of peginterferon alfa-2b. Use only if potential benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Evaluate renal function prior to initiating therapy and monitor closely during therapy;  use peginterferon alfa-2b with caution in patients with renal impairment; use is contraindicated if CrCl &lt;50 mL/minute; use in moderate renal impairment is not recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs); discontinue therapy if serum creatinine  &gt;2 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Avoid use in patients with chronic obstructive pulmonary disease (COPD); use caution in other pulmonary disease. Pulmonary effects (eg, pneumonitis, pulmonary infiltrates, pulmonary hypertension), sometimes fatal, have been reported.  Symptomatic patients should receive a chest x-ray; if pulmonary abnormalities are present, monitor patient closely. Discontinuation of therapy may be necessary.  Concomitant use of the herbal product Shosaikoto has been associated with increased reports of pulmonary symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sarcoidosis: Exacerbation of disease has been observed with use of peginterferon alfa-2b. Use only if potential benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Medications causing lactic acidosis: Use with caution in patient receiving medications which may cause lactic acidosis (eg, nucleoside analogues).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Avoid use in patients with severe debilitating medical conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; encephalopathy may be increased in the elderly as well as a higher frequency of anemia in older adults &gt;50 years of age and/or those with renal impairment &lt;50 mL/minute; monitor closely for anemia, particularly in the initial 4 weeks of therapy; evaluate renal function before initiating and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use during pregnancy is contraindicated; avoid pregnancy in female patients and female partners of male patients during ribavirin therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. Manufacturer recommends reporting pregnancies to (800) 463-5442. Negative pregnancy test is required before initiation and monthly thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferons.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Safety and efficacy have not been established in patients who have received organ transplants, have been coinfected with HIV or hepatitis B.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207116\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207082\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10256&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): Peginterferon Alfa-2b may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2b.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207095\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in pregnant women and males whose female partners are pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Abortifacient and/or teratogenic effects have been reported in animal studies with  interferons and ribavirin. If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy and/or contraception should be followed. Women of childbearing potential should not be treated unless two reliable forms of contraception are used. In addition, male patients and their female partners must also use two reliable forms of contraception. Pregnancy must be avoided during treatment and for 6 months following therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49076021\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The manufacturer recommends breast-feeding be discontinued during therapy. Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207096\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take oral formulation without regard to meals, but always in a consistent manner with respect to food intake (ie, always take with food or always take on an empty stomach).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207085\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CBC (pretreatment, at weeks 2 and 4 [or more frequently if indicated], and routinely during therapy), renal and liver function tests (pretreatment and routinely during therapy), lipids, TSH, and electrolytes; glucose (diabetic or symptomatic patients); uric acid (patients predisposed to gout); ECG (at baseline and during therapy) in patients with pre-existing cardiac disease; pretreatment and monthly pregnancy test for women of childbearing age; dental exams; neuropsychiatric monitoring during and for 6 months after discontinuing therapy (patients developing psychiatric or CNS problems); vision and hearing evaluations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum HCV RNA levels (pretreatment, 4,12, and 24 weeks after therapy initiation, 24 weeks after completion of therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate recommendations (AASLD/IDSA 2015):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (within 12 weeks prior to starting antiviral therapy): CBC, INR, hepatic function panel (albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase), calculated GFR, TSH</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline (at any time prior to starting antiviral therapy): HCV genotype and subtype, quantitative HCV viral load</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During therapy: CBC, serum creatinine, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6). TSH every 12 weeks during interferon therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207089\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Canadian consensus guidelines (Sherman 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rapid virological response (RVR): HCV RNA negative (&lt;50 units/mL) after 4 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Early virological response (EVR):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Early virological clearance (EVC): HCV RNA negative (&lt;50 units/mL) after 12 weeks of treatment <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Partial virological response (PVR): &ge;2-log decrease in HCV RNA but still positive for HCV RNA after 12 weeks of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sustained virological response (SVR): Absence of HCV RNA in the serum 6 months following completion of full treatment course</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207077\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peginterferon Alfa-2b: Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ribavirin: Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207093\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report-view. Updated 2015. Accessed September 16, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berg T, Von Wagner M, Nasser S, et al, &ldquo;Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin,&rdquo; <i>Gastroenterology</i>, 2006, 130(4):1086-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information/abstract-text/16618403/pubmed\" target=\"_blank\" id=\"16618403\">16618403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2006, 130(1):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information/abstract-text/16401485/pubmed\" target=\"_blank\" id=\"16401485\">16401485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo; <i>N Engl J Med</i>, 2006, 355(23):2444-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information/abstract-text/17151366/pubmed\" target=\"_blank\" id=\"17151366\">17151366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearlman BL, Ehleben C, and Saifee S, &ldquo;Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders,&rdquo; <i>Hepatology</i>, 2007, 46(6):1688-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-drug-information/abstract-text/18046717/pubmed\" target=\"_blank\" id=\"18046717\">18046717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed December 29, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10256 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207103\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207120\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F207106\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991839\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989125\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062248\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F207121\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F8012044\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234133\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F207091\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49322200\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207090\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26116837\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207080\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207094\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207078\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F207116\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207082\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F207095\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F49076021\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F207096\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F207085\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F207089\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207077\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F207093\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10256|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2b-and-ribavirin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Pegylated interferon (peginterferon) alfa-2b and ribavirin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}